PMID- 16984232
OWN - NLM
STAT- MEDLINE
DCOM- 20070419
LR  - 20060920
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 65
IP  - 4
DP  - 2006 Oct
TI  - Lower ability to oxidize lipids in adult patients with growth hormone (GH) 
      deficiency: reversal under GH treatment.
PG  - 423-8
AB  - BACKGROUND: The aim of the study was to characterize lipid oxidation at exercise 
      in adults with growth hormone deficiency (GHD) and to evaluate the effect of 6 
      and 12 months of GH replacement therapy on substrate carbohydrate (CHO) and lipid 
      utilization at exercise. PATIENTS AND MEASUREMENTS: Twenty-five patients with GHD 
      and 40 matched controls participated in the study. Ten of the 25 GH-deficient 
      patients were treated with recombinant GH for 12 months. Anthropometric 
      measurements and exercise calorimetry were performed before and after treatment. 
      Maximal fat oxidation and the crossover point [that is the percentage of the 
      theoretical maximal power (Wmax th) where CHO become the predominant fuel used 
      for oxidation] were determined. RESULTS AND CONCLUSION: The GH-deficient patients 
      exhibited a highly significant shift in the balance of substrate oxidation during 
      exercise, towards a decrease in fat oxidation, and a shift towards lower 
      intensities of the crossover (52 +/- 5.5%vs. 72.6 +/- 6.6% of Wmax th, P < 0.03) 
      and maximal fat oxidation (131.04 +/- 14 vs. 234.4 +/- 30.1 mg/min, P < 0.03) in 
      the GHD and control groups, respectively. However, GH treatment at 6 and 12 
      months partially reversed this defect, resulting in an increase (+83%, P < 0.001) 
      in the maximal ability to oxidize fat during exercise. These findings are 
      consistent with the hypothesis that a lack of GH reduces the ability to oxidize 
      lipids during exercise and that GH treatment restores this muscular metabolic 
      property.
FAU - Brandou, F
AU  - Brandou F
AD  - Service Central de Physiologie Clinique, Centre d'Exploration et de Readaptation 
      des Anomalies du Metabolisme Musculaire, CHU Montpellier, France. 
      fredbrandou@yahoo.fr
FAU - Aloulou, I
AU  - Aloulou I
FAU - Razimbaud, A
AU  - Razimbaud A
FAU - Fedou, C
AU  - Fedou C
FAU - Mercier, J
AU  - Mercier J
FAU - Brun, J F
AU  - Brun JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Adenoma/metabolism
MH  - Adult
MH  - Analysis of Variance
MH  - Body Composition
MH  - Carbohydrate Metabolism
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Energy Metabolism
MH  - Exercise/*physiology
MH  - Exercise Test/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Growth Hormone/*deficiency/metabolism
MH  - Human Growth Hormone/therapeutic use
MH  - Humans
MH  - Hypopituitarism/drug therapy/*metabolism
MH  - *Lipid Metabolism
MH  - Male
MH  - Muscle, Skeletal/metabolism
MH  - Oxygen Consumption
MH  - Pituitary Neoplasms/metabolism
MH  - Time Factors
EDAT- 2006/09/21 09:00
MHDA- 2007/04/20 09:00
CRDT- 2006/09/21 09:00
PHST- 2006/09/21 09:00 [pubmed]
PHST- 2007/04/20 09:00 [medline]
PHST- 2006/09/21 09:00 [entrez]
AID - CEN2578 [pii]
AID - 10.1111/j.1365-2265.2006.02578.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2006 Oct;65(4):423-8. doi: 
      10.1111/j.1365-2265.2006.02578.x.